Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 286 participants.
Also called NCT03070782
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 286 participants
- Registry
-
NCT03070782 -
2016-003373-18
-
- Other papers using this trial's data
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Denmark, Germany, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT03070782. Randomized; triple masking; primary purpose treatment. Start 2017-03-07 (actual); primary completion 2018-07-26 (actual). Results posted on 2020-10-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
- Condition
- Elevated Lipoprotein(a)
- Condition
- Cardiovascular Disease
- Intervention (Drug)
- ISIS 681257
- Intervention (Drug)
- Placebo
- Lead sponsor
- Akcea Therapeutics
- Collaborator
- Ionis Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct03070782- Content hash
d69fdc4d938e81068c1ea20c7ae06838b2413bce3c0551c34c50ec0d45a0682c